YANG Jingying,XIAO Yisheng,JIANG Jielin,et al.Clinical Study on Huangjing Pills in the Treatment of Mild and Moderate Alzheimer Disease[J].zhongguo zhongyiyao xinxi zazhi,2020,27(11):40-44.[doi:10.19879/j.cnki.1005-5304.202004098]
黄精丸治疗轻中度阿尔茨海默病临床研究
- Title:
- Clinical Study on Huangjing Pills in the Treatment of Mild and Moderate Alzheimer Disease
- 文章编号:
- 1005-5304(2020)11-0040-05
- Keywords:
- Huangjing Pills; Alzheimer disease; clinical study
- 分类号:
- R277.72
- 文献标志码:
- A
- 摘要:
- 目的 观察黄精丸治疗轻中度阿尔茨海默病（AD）临床疗效。方法 采用随机数字表法将97例轻中度AD患者分为对照组49例和研究组48例。对照组予盐酸多奈哌齐片，5 mg/d，口服；研究组予黄精丸，1丸/次，2次/d，口服。2组均1个月为1个疗程，疗程间停药1周，共治疗3个疗程。观察2组临床疗效，比较2组治疗前后简易精神状态检查量表（MMSE）评分、改良长谷川痴呆量表（HDS-R）评分、日常生活活动能力量表（ADL）评分，检测2组治疗前后血清超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、丙二醛（MDA）、白细胞介素-1β（IL-1β）水平，监测2组不良反应。结果 研究组总有效率为91.7%（44/48），对照组为81.6%（40/49），2组比较差异有统计学意义（P＜0.05）。与本组治疗前比较，2组治疗后MMSE、HDS-R、ADL评分明显升高（P＜0.05）；2组治疗后比较，研究组MMSE、HDS-R、ADL评分明显高于对照组（P＜0.05）。与本组治疗前比较，研究组治疗后血清SOD、GSH-Px活性升高，血清MDA、IL-1β水平降低（P＜0.05）；2组治疗后比较，研究组血清SOD、GSH-Px活性高于对照组，MDA、IL-1β水平低于对照组（P＜0.05）。对照组不良反应发生率为36.7%（18/49），研究组未见不良反应。结论 黄精丸治疗轻中度AD临床疗效较好，可改善患者痴呆症状，提高其认知功能及生活能力，降低机体氧化应激水平。
- Abstract:
- Objective To observe the clinical efficacy of Huangjing Pills in the treatment of patients with mild and moderate Alzheimer disease (AD). Methods Totally 97 patients with mild and moderate AD were divided into the control group and the study group according to random number table method, with 49 patients in the control group, and 48 patients in the study group. The control group was given routine treatment w ith donepezil hydrochloride tablets, 5 mg/d, orally. The study group was given Huangjing Pills, one pill each time, twice a day, orally. One month was a course of treatment, and then the medicine was stopped for 1 week. A total of 3 courses were treated. The clinical efficacy of both groups was observed. The scores of the Mini Mental State Examination Scale (MMSE), the modified Hasegawa Dementia Scale (HDS-R), and the Activity of Daily Living Scale (ADL) scores were compared between the two groups before and after treatment. Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), and interleukin-1β (IL-1β) levels were detected before and after treatment in the two groups. Adverse reactions in 2 groups were monitored. Results The total effective rate was 91.7% (44/48) in the study group and 81.6% (40/49) in the control group, with statistical significance ( P<0.05). Compared with before treatment, the scores of MMSE, HDS-R and ADL in the two groups were significantly increased (P<0.05); after treatment, the scores of MMSE, HDS-R and ADL in the study group were significantly higher than those in the control group (P<0.05). Compared with before treatment, the serum SOD and GSH-Px activities in the study group were increased after treatment, and the serum MDA and IL-1β levels were decreased (P<0.05). After treatment, the SOD and GSH-Px activities in the study group were higher than those of the control group, and the levels of MDA and IL-1β were lower than those of the control group ( P<0.05). The incidence of adverse reactions in the control group was 36.7% (18/49) , and there were no adverse reactions in the study group. Conclusion Huangjing Pills has good clinical efficacy on the treatment of AD. It can improve the symptoms of AD, improve the cognitive function and living ability, and reduce the level of oxidative stress of the body.
参考文献/References:
[1] SENGOKU R. Aging and Alzheimer’s disease pathology[J]. Neuropathology,2020,40(1)：22-29.
[2] STANCIU G D, LUCA A, RUSU R N, et al. Alzheimer’s disease pharmacotherapy in relation to cholinergic system involvement[J]. Biomolecules,2019,10(1)：E40. [3] 朱杰,张钊,董一筱,等.阿尔茨海默病及其治疗药物研究进展[J].中国药理学通报,2018,34(12)：1629-1634. [4] SINHH A, KUKRETI R, SASO L, et al. Oxidative stress：A key modulator in neurodegenerative diseases[J]. Molecules,2019,24(8)：E1583. [5] PRASAD K N. Oxidative stress and pro-inflammatory cytokines may act as one of the signals for regulating microRNAs expression in Alzheimer’s disease[J]. Mech Ageing Dev,2017,162：63-71. [6] PRASAD K N. Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer’s disease[J]. Mech Ageing Dev, 2016,153：41-47. [7] UMENO A, BIIU V, YOSHIDA Y. In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer’s disease, Parkinson’s disease, and diabetes[J]. Free Radic Res,2017,51(4)：413-427. [8] CHEN L, ZHANG C, HAN Y, et al. Gingko biloba extract (EGb) inhibits oxidative stress in neuro 2A cells overexpressing APPsw[J]. Biomed Res Int,2019,2019：7034983. [9] GÓMEZ-RAMOS A, DÍAZ-NIDO J, SMITH M A, et al. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells[J]. J Neurosci Res,2003,71(6)：863-870. [10] 王琳琳,胡镜清,张治国,等.中药及复方减少阿尔茨海默病氧化损伤研究探析[J].世界科学技术－中医药现代化,2019,21(1)：38-43. [11] 中国中医研究院中药研究所.全国中成药处方集[M].北京：人民卫生出版社,1962：73. [12] 周志军,肖移生.黄精丸对大鼠大脑局灶性脑缺血损伤保护作用研究[J].井冈山大学学报(自然科学版),2012,33(1)：88-90. [13] 杨晶莹,肖移生,姜劼琳,等.黄精丸对阿尔茨海默病大鼠大脑的抗氧化作用及Aβ1-42、APP蛋白表达的影响[J].中国实验方剂学杂志,2020, 26(6)：32-38. [14] 中国痴呆与认知障碍指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会.2018中国痴呆与认知障碍诊治指南(一)：痴呆及其分类诊断标准[J].中华医学杂志,2018,98(13)：965-970. [15] LOWE D A, BALSIS S, MILLER T M, et al. Greater precision when measuring dementia severity：establishing item parameters for the clinical dementia rating scale[J]. Dement Geriatr Cogn Disord, 2012,34(2)：128-134. [16] 傅仁杰.老年呆病(老年痴呆)的中医临床诊断及疗效评定标准(试行)[C]//全国中医药防治老年病学术交流会学术论文集.乌鲁木齐, 2011：22-23. [17] FOLSTEIN M F, FOLSTEIN S E, MCHUGH P R. “Mini-mental state”： a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res,1975,12(3)：189-198. [18] 曹德鹏,高之旭,方贻儒.改良长谷川痴呆量表在中老年期痴呆筛选中的应用[J].中国心理卫生杂志,1997,11(4)：213-215. [19] CHEON S M, PARK K W, KIM J W. Identification of daily activity impairments in the diagnosis of parkinson disease dementia[J]. Cogn Behav Neurol,2015,28(4)：220-228. [20] 李浩,王承华,王力.脑复益聪胶囊治疗老年性痴呆的临床观察[J].中国中医药信息杂志,2002,9(4)：20-22. [21] 程华丽,赵冬梅.补肾活血汤联合针灸治疗老年痴呆临床研究[J].河南中医,2017,37(4)：619-621. [22] 朱成全,肖烈钢,张玉亮.脑力智宝对老年性痴呆的影响[J].中国中医药信息杂志,2005,12(8)：5-6. [23] 张立敏,安红梅.中药复方辨证治疗老年痴呆的临床和实验进展[J].中华中医药学刊,2017,35(1)：124-126. [24] CHAUHAN A, CHAUHAN V. Beneficial effects of walnuts on cognition and brain health[J]. Nutrients,2020,12(2)：E550. [25] KOWALSKA M, WIZE K, PRENDECKI M, et al. Genetic variants and oxidative stress in Alzheimer’s disease[J]. Curr Alzheimer Res, 2020,17(3)：208-223.
相似文献/References:
[1]代 渊,王 飞,徐世军.中医治疗阿尔茨海默病优势述略[J].中国中医药信息杂志,2010,17(8):5.[doi:10.3969/j.issn.1005-5304.2010.08.003]
[J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):5.[doi:10.3969/j.issn.1005-5304.2010.08.003]
[2]冀俊虎,董联玲,曹娟,等.红景天对阿尔茨海默病大鼠行为学和脑组织抗氧化能力的影响[J].中国中医药信息杂志,2009,16(2):38.
JI Jun-hu,DONG Lian-ling,CAO Juan,et al.Effects of Integripetal Rhodiola Herb on Ethology and Anti-oxydation Potential of Brain Tissue of Alzheimer’s Disease Model Rats[J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):38.
[3]刘龙涛,李浩.浅谈APP转基因小鼠痴呆模型在中医药领域的应用[J].中国中医药信息杂志,2009,16(9):7.
[J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):7.
[4]陈玉静,田金洲,王蓉,等.金思维对散发性老年性痴呆模型大鼠学习记忆能力的影响[J].中国中医药信息杂志,2008,15(4):29.
CHEN Yu-jing,TIAN Jin-zhou,WANG Rong,et al.Effect of GETO on Learning and Memory of Sporadic Alzheimer’s Disease Rats[J].zhongguo zhongyiyao xinxi zazhi,2008,15(11):29.
[5]魏翠柏,贾建平,王芬,等.人参皂苷Rg1、Rb1对淀粉样前体蛋白分泌酶代谢途径的影响[J].中国中医药信息杂志,2008,15(9):28.
WEI Cui-bai,JIA Jian-ping,WANG Fen,et al.Effect of Ginsenoside Rg1 and Rb1 on Secretase in Metabolic Pathway of Amyloid Precursor Protein[J].zhongguo zhongyiyao xinxi zazhi,2008,15(11):28.
[6]李满生,徐厚谦,金华,等.寿聪胶囊对老年痴呆模型大鼠行为学及过氧化氢酶、单胺氧化酶的影响[J].中国中医药信息杂志,2008,15(10):34.
LI Man-sheng,XU Hou-qian,JIN Hua,et al.Effect of Shoucong Capsule on Learning-memorial Ability and CAT, MAO Activities in Alzheimer Disease Rats[J].zhongguo zhongyiyao xinxi zazhi,2008,15(11):34.
[7]朱晶,邵水金,崔国红,等.电针血清对β淀粉样蛋白损伤原代培养大鼠海马神经元的保护作用[J].中国中医药信息杂志,2013,20(10):38.[doi:10.3969/j.issn.1005-5304.2013.10.014]
ZHU Jing,SHAO Shui-jin,CUI Guo-hong,et al.Protective Effects of Electro-acupuncture Serum on β-amyloid Protein Induced Damage of Primarily Cultured Rat Hippcampal Neurons[J].zhongguo zhongyiyao xinxi zazhi,2013,20(11):38.[doi:10.3969/j.issn.1005-5304.2013.10.014]
[8]张松峰,雷蕾,方锐,等.防治阿尔茨海默病药食同源类中药配伍规律研究[J].中国中医药信息杂志,2013,20(11):22.[doi:10.3969/j.issn.1005-5304.2013.11.009]
ZHANG Song-feng,LEI Lei,FANG Rui,et al.Literature Research of Compatibility Laws of Homologous Chinese Medicine of Medicine and Food in Prevention and Treatment of Alzheimer Disease[J].zhongguo zhongyiyao xinxi zazhi,2013,20(11):22.[doi:10.3969/j.issn.1005-5304.2013.11.009]
[9]刘畅,王梦之,国海东,等.电针对阿尔茨海默病大鼠单核细胞趋化蛋白-1及基质细胞衍生因子-1的影响[J].中国中医药信息杂志,2014,21(5):43.[doi:10.3969/j.issn.1005-5304.2014.05.014]
LIU Chang,WANG Meng-zhi,GUO Hai-dong,et al.Effects of Electro-acupuncture on Expression of Chemokines MCP-1 and SDF-1 in Alzheimer’s Disease Rats[J].zhongguo zhongyiyao xinxi zazhi,2014,21(11):43.[doi:10.3969/j.issn.1005-5304.2014.05.014]
[10]徐凯,卫东锋,张仰君,等.知母及其提取物改善学习记忆和治疗阿尔茨海默病研究进展[J].中国中医药信息杂志,2014,21(6):132.[doi:10.3969/j.issn.1005-5304.2014.06.046]
[J].zhongguo zhongyiyao xinxi zazhi,2014,21(11):132.[doi:10.3969/j.issn.1005-5304.2014.06.046]
备注/Memo
基金项目：江西省卫生健康委员会2020年度科技计划（20203772）；江西省卫生健康委员会中医药科研计划课题（2018B014）；2018年江西中医药大学“双一流”学科建设项目（2018SYLXK028）；江西省“双一流”学科（中医学）建设项目（JXSYLXK-ZHYI051） 通讯作者：姜劼琳，E-mail：357566941@qq.com
更新日期/Last Update:
2020-10-19